Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Landmark Trials > Obstetric > Flashcards

Obstetric Flashcards

1
Q

Immediate delivery vs. expectant for PPROM near term (PPROMT).
Journal, year, author, aim

A

Lancet, 2016.
Morris et al.
To establish if immediate delivery in PPROM at 34-36+6 reduces neonatal infection without increasing morbidity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Immediate delivery vs. expectant for PPROM near term (PPROMT).
Methodology

A

Multicentre RCT, 11 countries. 2004-2013.
1839 women.
>16y, singleton pregnancies, PPROM 34-36+6.
IOL within 24h vs. unit led monitoring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Immediate delivery vs. expectant for PPROM near term (PPROMT).
Results

A 
Neonatal sepsis (primary outcome) 2% vs. 3% - not significant. In immediate delivery, neonates had increased respiratory distress, mechanical ventilation and NICU time. Higher CS rate for mothers. 
Expectant - women had higher APH rate, use of PP antibiotics and longer hospital stay
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Immediate delivery vs. expectant for PPROM near term (PPROMT).
Conclusions.

A

Expectant management should be practised as immediate delivery was shown to increase neonatal complications and likelihood of c-section. However women need to be closely monitored as they had a higher incidence of APH and infection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Immediate delivery vs. expectant for PPROM near term (PPROMT).
Strengths.

A

65 centres, 11 countries. RCT. Blinded panel who decided on primary outcome. Good follow up (only 5 women not accounted for)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Immediate delivery vs. expectant for PPROM near term (PPROMT).
Weaknesses

A

PPROM <34/40 included once 34/40
Study duration 9y.
Expectant management not specified

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Broad-spec antibiotics for PPROM - ORACLE I.

Journal, year, author, aim

A

Lancet, 2001
Kenyon et al
Do antibiotics administered to the mother in PPROM improve neonatal health and long-term outcomes by preventing infectious morbidity in the fetus or delay PTB?

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Broad-spec antibiotics for PPROM - ORACLE I.

Methodology

A

RCT, intention to treat, placebo controlled. UK and other international centres. 4826 women.
4 groups: Erythromycin, augmentin, both, placebo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Broad-spec antibiotics for PPROM - ORACLE I.

Results

A

Erythromycin - prolonged pregnancy, and reduced surfactant requirement, major cerebral abnormalities, positive blood culture. Composite primary outcome (NND, chronic lung disease, major cerebral abnormality on USS) when look at singleton pregnancies.
Augmentin, and both - prolonged pregnancy but increased NEC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Broad-spec antibiotics for PPROM - ORACLE I.

Conclusions

A

Erythromycin for women with PPROM has a myriad of health benefits for neonate and probable reduction in childhood disability, particularly in singleton pregnancy. Augmentin associated with increased risk of NEC and therefore not recommended.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Broad-spec antibiotics for PPROM - ORACLE I.

Strengths

A 
Only 2 women lost to follow-up, 15 protocol violations
379 centres participated
Large RCT-blinded
Clinically very relevant
A lot of subanalysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Broad-spec antibiotics for PPROM - ORACLE I.

Limitations

A

11 cases had medicines revealed and data was included in analysis
Limited info of study population were collected e.g. previous obstetric history or maternal disease.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Hyperglycaemia and adverse pregnancy outcomes (HAPO)

Journal, year, author, aim

A

NEJM, 2008
HAPO study cooperative research group (Metzfer et al)
To assess whether maternal hyperglycaemia below the threshold for diabetes Dx was a/w adverse pregnancy outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Hyperglycaemia and adverse pregnancy outcomes (HAPO)

Methodology

A

Observational study
~23,000
75g OGTT - stratified into 7 groups depending on result
Patients and staff blinded

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hyperglycaemia and adverse pregnancy outcomes (HAPO)

Results

A

Frequency of primary outcomes (BW >90th, cord blood C peptide >90th, primary CS and neonatal hypoglycaemia) increased with increasing glucose category
- Strongest for birthweight and C peptide
Also positive associations with 5 secondary outcomes (should dystocia or birth injury, prematurity, need for NICU, PET, hyperbilirubinaemia)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hyperglycaemia and adverse pregnancy outcomes (HAPO)

Strengths

A

Multi-centre observational study, OGTTs validated at single lab
Adds weight to ACHOSIS (reduced perinatal morbidity and mortality with treatment of GDM)
Clinicians and patients blinded to result of OGTT
Biologically plausible – results support the Pedersen hypothesis (maternal hyperglycaemia –> fetal hyperglycaemia –> exaggerated response to insulin)
Limited caregiver bias as patients and staff (other than lab staff) were blinded to result of OGTT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Hyperglycaemia and adverse pregnancy outcomes (HAPO)

Limitations

A

Statistically underpowered for rare severe outcomes (e.g. perinatal deaths)
Threshold effect not established
No info on BMI or weight gain of mothers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Hyperglycaemia and adverse pregnancy outcomes (HAPO)

Conclusions

A

On average, maternal glucose levels (less than those meeting the criteria for DM diagnosis at the time) are associated with increased birth weight and neonatal insulin levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Effect of treatment of gestational diabetes mellitus on pregnancy outcomes (ACHOIS)
Journal, year, author, aim

A

NEJM, 2005
Crowther et al
To establish that screening and treatment of women with gestational diabetes reduces the risk of perinatal complications

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Effect of treatment of gestational diabetes mellitus on pregnancy outcomes (ACHOIS)
Methodology

A

RCT
1000 women

Dietary advice, glucose monitoring and insulin treatment vs. routine care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Effect of treatment of gestational diabetes mellitus on pregnancy outcomes (ACHOIS)
Results

A

Composite serious neonatal outcomes were lower in intervention group - 1% vs 4%, NNT 34

Intervention group had more:

  • NICU admissions 71 vs 61% (but no increase in secondary outcomes such as hypoglycaemia requiring IV etc)
  • IOL 39 vs 29%
  • Better post-partum health survey results

No difference in the rate of caesarean sections and phototherapy requirements

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Effect of treatment of gestational diabetes mellitus on pregnancy outcomes (ACHOIS)
Conclusions

A

Treatment of mild GDM for glycaemic control reduces the rate of serious perinatal complications without increasing the rate of caesarean section

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Effect of treatment of gestational diabetes mellitus on pregnancy outcomes (ACHOIS)
Limitations

A

OGTT those in routine told no GDM regardless of result of OGTT - ?ethics of this once
WHO guidelines changed
Nil criteria for routine care (depended on local guidelines) may have varied
?appropriateness of use of composite outcomes given rare neonatal outcomes
?power of study with numbers given rare neonatal outcomes
Outcomes measured are not unique to GDM
- 5 stillbirths in intervention group (APH, 2 unexplained, 1 lethal abnormality, 1 IUGR + PET)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Magpie trial

Journal, year, author, aim

A

Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate?
Lancet, 2002
Magpie Trial Collaberative group
Aim = title

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Magpie trial

Methodology

A

International, double blind, placebo controlled, RCT
10,100 women
Intention to treat

Antenatal or <24hr post-partum
Women with PET and there was uncertainty about whether to use MgSO4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Magpie trial

Results

A

Primary outcomes

  • Eclampsia - reduced risk by 58%. NNT 91, 63 for severe PET.
  • Death of baby before discharge - no difference

Secondary outcomes:

  • Not significant reduction in maternal death (45%)
  • 24% experienced side effects vs. 5%
  • 27% lower RR of abruption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Magpie trial

Conclusions

A

MgSO4 reduces the risk of eclampsia, likely reduces the risk of maternal death
At this dosage, it does not have any substantive harmful effects on the mother or child, although a quarter of women will have side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Magpie trial

Strengths

A 
Multi-centre, large study
Double blind
Randomised
Generalisabled to a large range of clinical settings (both rich and poor countries)
Good follow up - 99.7% of women
Intention to treat analysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Magpie trial

Weakness

A

IV and IM - variable route of administration
Side effects may have allowed the allocation to be guessed
Eligibility dependent on attending clinicians’ beliefs about MgSO4 - unable to keep an accurate record of those eligible but not recruited

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

TRUFFLE

Journal, year, author, aim

A

2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial
Lees et al
The Lancet, 2015

Aim: To establish is changes in fetal ductus venosus doppler waveform could be used as indications for delivery instead of CTG short-term variation (STV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

TRUFFLE

Methodology

A

Multicentre, randomised management trial
Europe

Women admitted to hospital with singleton pregnancies and diagnosed with FGR

  • AC <10th and abnormal UA PI >95th (+/- AREDF)
  • EFW >500g
  • Normal DV and short term variation

Group 1 = STV <3.5ms (<29/40), <4ms (>/=29/40)
Group 2 = early ductus changes
Group 3 = DV no A wave

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

TRUFFLE

Conclusions

A

No significant difference in the proportion of infants surviving without neuroimpairment. However timing of delivery based on late changes in DV waveform might product an improvement in developmental outcomes at 2y.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

TRUFFLE

Strengths

A

Randomised
Intention to treat study
Independent review of data yearly
Paediatrics doing f/u were masked to allocation group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

TRUFFLE

Weaknesses

A

Women were closely looked after by specialist MFM experts, this may be generalisable as not all women have access to this
CTG monitoring was based on computerised assessment of fetal heart STV
- Not all hospitals have this
High proportion of infants triggered safety net delivery criteria
- 38% overall
- 52% in late DV changes group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

CLASP

Journal, year, author, aim

A

A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women.
Redman et al
Lancet, 1994
To determine the safety of LDA and if it reduces fetal / neonatal morbidity and mortality, either overall or in selected high risk groups

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

CLASP

Methodology

A

Multicentre RCT
>9000 women
Double blinded trial - 60mg Aspirin or matching placebo tablet

Inclusion criteria:
>8//40
Prophylactic: history of PET or IUGR, chronic HTN, renal disease or other risk factors e.g. maternal age
Therapeutic: signs or symptoms in current pregnancy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

CLASP

Results

A

Statistically significant reduction in proteinuria PET if entered the study before 20/40 - NNT 100

Reduced likelihood of delivery before 37/40

No statistically significant change for:

  • IUGR
  • Stillbirths and neonatal deaths

For evidence for bleeding side effects (e.g. abruption)

All outcomes were more statistically significant for early onset PET <32 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

CLASP

Conclusions

A

Use low dose aspirin in those women who may be justified as high risk of early onset PET <32 weeks and start before 20 weeks gestation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

CLASP

Strengths

A

Double blind RCT – low risk of bias
Large cohort of entrants
Intention to treat analysis
Clinically relevant in a New Zealand setting
- MMH was a trial centre as well as several Australian centres

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

CLASP

Weakness

A

PET diagnosis not standard

- E.g. rise in DBP >25mg if <90 at booking or 15mmHg is greater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

ACTORDS

Journal, year, author, aim

A

Neonatal Respiratory Distress Syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial (ACTORDS)
Crowther et al
Lancet, 2006

Establish if repeat prenatal corticosteroids given to women at risk of preterm birth can reduce neonatal morbidity without harm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

ACTORDS

Methodology

A

982 women
Australia and NZ
Double-Blind RCT
Intention to treat analysis

Women at risk of preterm birth <32/40 (singleton or multiple)
≥7 days after receiving first course of steroids
Ongoing risk for PTB

IM 11.4mg Betamethasone or Placebo (Saline) given weekly, if women remained undelivered and <32/40 with ongoing risks of preterm birth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

ACTORDS

Results

A

Primary outcomes

- Less RDS (NNT 14)
- Less oxygen therapy (NNT 15)
- Shorter duration of mechanical ventilation 
- No difference in weight/length/HCat birth or discharge

Steroid group

- Fewer severe lung disease (NNT 14)
- CS birth and more minor maternal side-effects

No difference in

  • Rates of NICU admission
  • Length of stay
  • IVH
  • Necrotising enterocolitis
  • Chorioamnionitis requiring intrapartum IV abx or pyrexia ≥ 38.0 ®C
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

ACTORDS

Conclusions

A

Repeat doses of antenatal corticosteroids reduced neonatal morbidity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

ACTORDS

Strengths

A 
Similar 2 groups
RCT
Independent data monitoring committee
Blinded
Given information regarding the safety profile of steroids for maternal and fetal
Did follow up at 2y and 6-8y
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

ACTORDS

Weakness

A

Only studied up to 32/40

Wide range of gestational age, treatment doses and number of doses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomised placebo-controlled double blind study

Journal, year, author, aim

A

da Fonseca et al.

AJOG (American Journal of Obstetrics and Gynaecology) , 2003

To evaluate if prophylactic administration of progesterone by pessary can reduce the risk of incidence of preterm birth in a high risk population

48
Q

Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk

Methodology

A

Double blind RCT - 100mg of progesterone daily or placebo from 24-34/40

Brazil
142 women

Included women – 24+/40, asymptomatic at time of randomisation and had at least one of:

  • Previous preterm birth
  • Uterine malformation
  • Prophylactic cervical cerclage in this pregnancy

Excluded multiple pregnancy and fetal malformation

49
Q

Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk

Results

A

PTB lower in intervention group

Fewer recordable UA events
- Weekly 60 min recording of contractions

50
Q

Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk

Conclusions

A

Prophylactic vaginal progesterone reduced the frequency of uterine contractions and rate of preterm delivery in high risk women

51
Q

ACTORDS long term follow up

A

Administration of repeat doses of AN corticosteroids reduces neonatal morbidity without changing either survival free of major neurosensory disability or body size at 2y

Treatment with repeat dose(s) associated with neither benefit nor harm in mid-childhood (6-8y)

52
Q

Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk

Strengths

A

Double blind RCT – low risk of bias
Most women had a previous preterm birth
- This is the single biggest risk factor
Clinically relevant in a New Zealand setting

53
Q

Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk

Weaknesses

A

Very high risk population (baseline preterm birth rate of 25% for all women birthing at this hospital)
Small numbers
Gestation at intake was 24+/40 – would have been ideal to see if any value in starting earlier
Mechanism of action not completely understood
No comparison to cerclage alone

54
Q

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus: Intervention review

journal, year, author, aim

A

Doyle et al
Cochrane, 2009

To assess the effects of magnesium sulphate as a neuroprotective agent when given to women considered at risk of pre-term birth

55
Q

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus: Intervention review

methodology

A

5 RCTs of antenatal MgSO4 whose primary outcomes including neuroprotection

6145 babies

MAGPIE only study that looked at eclampsia

56
Q

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus: Intervention review

results

A

Significantly reduced risk of:

- Cerebral palsy, NNT 63
- Substantial gross motor dysfunction

No overall significant effect on:

- Paediatric morality
- Serious adverse maternal events

Significantly more women in magnesium group ceased therapy due to side effects

57
Q

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus: Intervention review

conclusion

A

The evidence now supports a role for antenatal magnesium sulphate in women at high risk of preterm birth as a neuroprotective agent particularly noticeable for those who delivered below 34 weeks.

58
Q

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus: Intervention review

strengths

A

Large cohort of babies
Only one study from developing country so applicable to our population
Meta-analysis of RCTs

59
Q

Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus: Intervention review

weaknesses

A

Babies were only followed up to 2 years old with developmental milestones
- Some cases of cerebral palsy may be missed therefore overpowering the effect of magnesium sulphate

? Diluted benefit as included babies up to 37 weeks
- Subgroup analysis showed greater effect in those <34/40

60
Q

Progesterone and Risk of Preterm Birth Among Women with Short Cervix

journal, year, aim, author

A

Fonseca et al

The New England Journal of Medicine, 2007

To evaluate if progesterone reduces early preterm delivery in asymptomatic women found at mid-gestation to have a short cervix

61
Q

Progesterone and Risk of Preterm Birth Among Women with Short Cervix

methodology

A

Multi-centered double-blind RCT

250 short cervix and agreed to participate
Cervical length of ≤15mm on TV USS

singleton or twin pregnancy undergoing routine USS 20-25/40 or fetal anatomy

Exclusion:

  • Major fetal abnormality
  • History of ruptured membranes
  • Cervical cerclage

Vaginal progesterone 200mg nocte 24-33+6 vs. placebo

62
Q

Progesterone and Risk of Preterm Birth Among Women with Short Cervix

results

A

Primary outcomes = Spontaneous delivery before 34 week

  • 19.2% vs 34.4%
  • lower in pv progesterone group
  • Especially if no history of PTB or singleton pregnancy

Non-significant reduction in neonatal morbidity

63
Q

Progesterone and Risk of Preterm Birth Among Women with Short Cervix

conclusion

A

In asymptomatic women with short cervix, treatment with progesterone reduces rate of spontaneous delivery before 34w

64
Q

Progesterone and Risk of Preterm Birth Among Women with Short Cervix

Strengths

A

Screened >24,000 women

Good adherence rate
Intention-to-treat
Double-blind RCT

65
Q

Progesterone and Risk of Preterm Birth Among Women with Short Cervix

Weaknesses

A

USS detection of cervical length- a lot of potential inconsistencies between sonographer
High number of USS required to identify asymptomatic shortened cervix ?cost-benefit
Length of <15mm - different to current practice

66
Q

ARRIVE

journal, year, author, aim

A

Labor Induction versus Expectant Management in Low risk Nulliparous Women

Grobman et al

NEJM, 2018

Perinatal and maternal consequences of IOL at 39/40 among low risk nulliparous women are uncertain

67
Q

ARRIVE

methodology

A

Multicentre RCT, USA
Low risk nulliparous women - randomised between 38-38+8
- Accurately dated by early USS or FAS + LMP congruent

Just over 6000 women

IOL at 39-39+4 vs. expectant management
EM - delivery initiated 40+5 to 42+2

68
Q

ARRIVE

results

A

Primary outcomes = Composite of perinatal death or severe neonatal complications
- No difference in perinatal death / severe neonatal complications

Significantly lower rate of CS in IOL group
- NNT to avoid 1 CS - 28

Women in IOL group also significantly:

  • Less likely to have hypertensive disorders of pregnancy
  • Less likely to have extensions of uterine incision during CS
  • Reported less pain
  • More perceived control during childbirth
69
Q

ARRIVE

conclusion

A

IOL at 39/40 in low risk P0 women did not result in a significantly lower frequency of composite adverse perinatal outcome
Did result in a significantly lower frequency of CS

70
Q

ARRIVE

strengths

A

Large RCT

71
Q

ARRIVE

weaknesses

A

Selection bias
Not blinded - unable to be
- Ascertainment bias

Still needs evaluation of cost-effectiveness

? comparison of early vs late indication as allowed maternal request induction from 40+5

72
Q

Antenatal betamethasone for women at risk of late preterm delivery

journal, year, author, aim

A

Gyamfi-Bannerman et al

NEJM 2016

To assess if betamethasone given to late preterm babies reduced rate of neonatal morbidity

73
Q

Antenatal betamethasone for women at risk of late preterm delivery

methodology

A

Randomised control trial
Intention to treat analysis
2831 participants

Singleton pregnancy at high probability of late pre-term delivery 34+0 – 36+6
- PTL, PPROM, planned IOL or CS

Excluded if previous course of antenatal steroids

Betamethasone 11.4mg or placebo, dose repeated 24 hours later

74
Q

Antenatal betamethasone for women at risk of late preterm delivery

results

A

Neonatal composite of the need for respiratory support in the first 72 hours after birth or stillbirth / neonatal death

  • significantly lower in steroid group
  • NNT for respiratory support = 35
  • no perinatal deaths

Secondary outcomes in intervention group:

  • Less resuscitation and surfactant required
  • Shorter stay in NICU
  • Increase in neonatal hypoglycaemia
  • No difference in chorio or neonatal sepsis
75
Q

Antenatal betamethasone for women at risk of late preterm delivery

strengths

A

RCT
Double blinded
Indications to give steroids clinically relevant to practice
High FU rate
Intention to treat method
- Only 60% (~800) patients received both doses of randomised medication, as others delivered before second dose given

76
Q

Antenatal betamethasone for women at risk of late preterm delivery

weaknesses

A

Need longer follow up to see if decrease in bronchopulmonary dysplasia has long term benefit
Study did not allow use of tocolysis
- Might increase effects seen
BSLs not measured routinely ? missed represented effect
24 hours after medication, management guided by local guidelines

77
Q

Antenatal betamethasone for women at risk of late preterm delivery

weaknesses

A

Need longer follow up to see if decrease in bronchopulmonary dysplasia has long term benefit
Study did not allow use of tocolysis
- Might increase effects seen
BSLs not measured routinely ? missed represented effect
24 hours after medication, management guided by local guidelines

78
Q

Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial.

author, year, journal, aim

A

Hannah et al.
The Lancet, 2000

To determine whether planned caesarean section was better than planned vaginal birth for selected breech-presentation pregnancies at term

79
Q

TERM BREECH

methodology

A

Randomised controlled trial
26 countries
2088 women

Intention to treat analysis
Followed-up until 6 weeks post partum

Singleton live fetus in a frank or complete breech presentation at >37 weeks

Excluded if:

  • Evidence of fetopelvic disproportion
  • Fetus clinically large or EFW >4000g
  • Hyperextension of fetal head
  • Fetal anomaly
  • Contraindication to labour or vaginal delivery

Planned C/S - 38+ weeks
Planned vaginal birth
- Expectant, unless indication for IOL or C/S developed

80
Q

TERM BREECH

results

A

Primary outcomes = Perinatal mortality, neonatal mortality, or serious neonatal morbidity

Significantly lower risk of combined primary outcome in planned C/S group (1.6% vs. 5%)
- NNT 14

56.7% delivered vaginally in planned vag group

No significant differences in maternal outcomes

Reduction in risk was much greater in countries with a low perinatal mortality rate

Trial was stopped early owing to a higher event rate than expected

At 2y risk of death or neurodevelopmental delay was no different between the two groups

81
Q

TERM BREECH

Strengths

A

Large, multicentre RCT

Subsequent publication of four large European population studies all show an improved neonatal outcome after elective caesarean for breech

82
Q

TERM BREECH

Weaknesses

A

Only 56.7% of those allocated to planned vaginal breech had a vaginal birth
Standard of care was not consistent
Hard to compare low and high perinatal mortality countries

2 stillbirths included in vaginal birth group who likely died before enrolment

High rate of protocol violations in vag group
- E.g. no USS to exclude extended neck, FGR babies included

Some of the risk is due to the earlier gestation at which elective CS is performed

83
Q

TERM BREECH

Conclusion

A

Planned C/S is better than planned vaginal birth for the term fetus in the breech presentation, with the benefits being greater in countries that are reported to have lower perinatal mortality rates

Serious maternal complications are similar between the groups

84
Q

TERMPROM

Author, aim, journal, year

A

Induction of labour compared with expectant management for prelabour rupture of the membranes at term

Hannah et al.

NEJM, 1996

85
Q

TERMPROM

methodology

A

Multicentre, randomised controlled trial
Intention to treat analysis
5041 women

Ruptured membranes, >37 weeks, single fetus, cephalic

  1. Labour induced immediately with oxytocin
  2. Labour induced immediately with prostaglandin gel
  3. Expectant (oxytocin) management (unless evidence of fetal or maternal compromise, or 4 days elapsed), with IOL if needed via oxytocin
  4. Expectant (PG) management
86
Q

TERMPROM

results

A

Primary outcomes - Definite or probable neonatal infection
- no difference

Women induced with oxytocin had lower rate of maternal infection
Intervention viewed more positively by women
~10% of those in the expectant group requested IOL

No difference:
- CS

87
Q

TERMPROM

conclusion

A

Oxytocin IOL associated with reduced risk of maternal infection
No difference in rate of neonatal infection, C/S rate

88
Q

TERMPROM

Strengths

A

Large, multicentre, randomised
Compared different IOL methods
When reviewing data collected on babies with signs of infection, committee was blinded to group assignments

89
Q

TERMPROM

weaknesses

A

Would need larger study to detect possible effect on perinatal mortality
Large time interval for expectant management, did not look at shorter time interval to start IOL, e.g. 24h, 48h

Did not look at effect of increasing parity (separated to 0 and >1)

Cochrane 2017

  • reduced maternal infection, chorio
  • less likely neonatal sepsis, antibiotics or admission to NICU
  • not significant reduction in CS
90
Q

ORACLE I 7y follow up

Journal, year, author, aim

A

Kenyon et al

Lancet, 2008

to determine any differences in functional and educational ability in childhood up to 7 years old between antibiotics and placebo groups and erythromycin vs co-amoxiclav

91
Q

ORACLE I 7y f/u

outcomes

A

The findings of decreased neonatal morbidity after the receipt of erythromycin in ORACLE I have not translated into long term benefit

No evidence of either antibiotic effecting any functional impairment, behavioural difficulties or exam attainment

92
Q

HYPITAT

journal, year, author, aim

A

Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks gestation (HYPITAT): a multicentre, open label randomised controlled trial.

Koopmans et al.

The Lancet, 2009

To assess whether induction of labour in women with gestational hypertension or mild pre-eclampsia beyond 36/40 reduces poor maternal outcomes c.f. expectant monitoring

93
Q

HYPITAT

method

A

Multicentre, open-label randomised controlled trial
Netherlands

Intention to treat analysis
756 patients

Singleton pregnancy at 36+0 to 41+0 with gest HTN or mild PET

Induction of labour within 24h of randomisation vs. expectant monitoring (“frequent’ BP monitoring + maternal assessment of FM + CTGs)

94
Q

HYPITAT

results

A

Primary outcomes = Composite measure of poor maternal outcome (mortality, eclampsia, HELLP, pulmonary oedema, thromboembolic disease, placental abruption, progression to severe HTN or proteinuria, major PPH)

  • significantly better for IOL group
  • NNT 8
  • Improvement based on significant reduction in need for anti-hypertensives and progression to severe HTN

IOL tended towards less CS but not significant
Neonatal outcomes equivalent between the two groups

Subgroup analysis
- Expectant management favoured in women 36-37 weeks

95
Q

HYPITAT

conclusion

A

Induction of labour is associated with improved maternal outcome and should be advised for women with mild hypertensive disease beyond 37 weeks’ gestation (as per study)

96
Q

HYPITAT

strengths

A

Multi-centre RCT with intention to treat analysis
Study design reflects real world practice limitations
Biologically plausible – IOL prevents progression to severe disease by shortening time to delivery

97
Q

HYPITAT

weaknesses

A

Composite outcome
Half of those randomised to expectant had IOLs anyway
Open label – possibility of bias
80% + white, other ethnicity data not specified
Statistically insignificant in improving severe outcomes – however may have been underpowered to do this

98
Q

WOMAN

journal, year, author, aim

A

Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

WOMAN Trial Collaborators
Lancet, 2017

Effects of early administration of TXA on maternal outcomes

99
Q

WOMAN

method

A

RCT, Double-blinded
21 countries
20,000 women
Intention to treat

≥16 years old
Clinical diagnosis of PPH

Intervention

  • 1g slow IV injection TXA +/- repeat at 30 mins if ongoing bleeding or bleeding restarted within 24h
  • IV placebo +/- second dose

Followed up to day 42 after delivery

100
Q

WOMAN

results

A

No difference in primary outcome = Composite of death from all causes or hysterectomy within 42 days of randomisation

Maternal death due to bleeding was significantly reduced in women given TXA

Adverse events did not different by group

No difference in

  • VTE
  • need for blood products
  • hysterectomy
  • death from all causes
101
Q

WOMAN

strengths

A

Multicentre, double blinded, RCT
Large study population
Very few participants lost to follow up

102
Q

WOMAN

weaknesses

A

Sample size increased midway through study

? generalisable in high income country
- In low income countries, hysterectomy is an early intervention due to more anaemia and less availablility of blood products

All-cause mortality not generalisable between countries
• Mainly low-mid income countries

Limited follow up to 42 days if still in hospital or earlier if discharged

103
Q

WOMAN

conclusion

A

TXA reduces death due to bleeding in women with PPH with no adverse effects
In patients treated with TXA within 3 hours of birth, TXA reduced death due to bleeding by one third

104
Q

ASTECS

journal, year, aim, author

A

Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial (ASTECS)

Stutchfield et al.
BMJ, 2005

To test whether steroids reduce respiratory distress in babies born by elective caesarean section at term

105
Q

ASTECS

method

A

Multicentre, pragmatic randomised trial
942 babies available for intention-to-treat analysis

Women having elective C/S planned >37/40, singleton pregnancies

Two IM doses of 12mg betamethasone in the 48h before delivery (24h apart)
Control group received treatment as usual

106
Q

ASTECS

results

A

Primary outcomes = admission to SCBU with respiratory distress
- Reduced in intervention group

Intervention group had:

  • Less TTN
  • Less RDS
  • Less ICU care

Adverse effects in 7 mothers in treatment group (flushing, nausea, pain, insomnia)

107
Q

ASTECS

strengths

A

RCT
Found that steroids reduced TTN - authors thought this was the first report of this
Generalisable to our population
Biological plausibility

108
Q

ASTECS

weaknesses

A

Unblinded

109
Q

ASTECS

conclusion

A

AN betamethasone and delayed delivery until 39 weeks both reduce admissions to SCBU with respiratory distress after elective C/S at term

110
Q

A Randomised Trial of Planned Caesarean or Vaginal Delivery for Twin Pregnancy.

journal, year, author, aim

A

Barret et al
New England Journal of Medicine, 2013

To assess if twins have better perinatal outcomes with vaginal delivery vs caesarean section

111
Q

A Randomised Trial of Planned Caesarean or Vaginal Delivery for Twin Pregnancy.

method

A

Multicentre international randomised control trial
2804 participants

32+0 - 38+6 live twins, leading twin cephalic, EFW 1500-4000g

Exclusion:

- Selective IUGR
- Contraindication to NVD

Planned caesarean section vs vaginal delivery.

112
Q

A Randomised Trial of Planned Caesarean or Vaginal Delivery for Twin Pregnancy.

results

A

No significant difference in neonatal death or morbidity or maternal composite outcome (2.2 vs 1.9%)
Higher risk of adverse perinatal outcome for second twin than first twin
- Planned caesarean section did not reduce this risk

4.2% had combined vaginal + c/s for second twin

The rate of caesarean delivery was:
- 90.7% in the planned CS group
- 43.8% in the planned vaginal delivery group
Women in the planned CS group delivered earlier

Post hoc subgroup analysis
- No significant interaction of chorionicity with the primary outcome

113
Q

A Randomised Trial of Planned Caesarean or Vaginal Delivery for Twin Pregnancy.

conclusions

A

Planned caesarean section when the first twin is cephalic did not significantly reduce the risk of adverse perinatal outcomes

114
Q

A Randomised Trial of Planned Caesarean or Vaginal Delivery for Twin Pregnancy.

strengths

A

Randomised controlled trial with high follow up rate

115
Q

A Randomised Trial of Planned Caesarean or Vaginal Delivery for Twin Pregnancy.

weaknesses

A

Only generalisable to units where obstetrician available for birth (most)
No standardised approach to delivery planning
High rate of caesarean section in vaginal delivery group- 40%
Need further study into outcomes for 37-38 week subgroup
- limited number of infants in this group
- Not appropriately powered for subgroup analysis

No comparison of IOL vs. CS

Landmark Trials (2 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions